AstraZeneca gains FDA approval of anticoagulant Brilinta

07/20/2011 | Wall Street Journal, The

AstraZeneca's Brilinta, or ticagrelor, was approved by the FDA for preventing blood clots in patients with acute coronary syndrome. In clinical tests, Brilinta proved "more effective than Plavix in preventing heart attacks and death, but that advantage was seen with aspirin maintenance doses of 75 to 100 milligrams once daily," the agency said. Brilinta will carry a boxed warning about bleeding risk and reduced effectiveness if taken with more than 100 milligrams of aspirin. Sanofi and Bristol-Myers Squibb market Plavix.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC